Affinity DataIC50: 1.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 1.60nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 1.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 1.90nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.10nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.30nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.5nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 2.90nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.10nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.20nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.30nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 3.90nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.30nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.30nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.30nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.5nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.60nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.60nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.80nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
TargetNeurogenic locus notch homolog protein 1/Recombining binding protein suppressor of hairless(Homo sapiens (Human))
Bristol-Myers Squibb
US Patent
Bristol-Myers Squibb
US Patent
Affinity DataIC50: 5.10nMAssay Description:The Notch-CBF1 (C-promoter binding factor I) cell based transactivation assay is based on the ability of the released Notch intracellular domain frag...More data for this Ligand-Target Pair
Affinity DataIC50: 5.40nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair
Affinity DataIC50: 5.70nMAssay Description:The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays.More data for this Ligand-Target Pair